Shan Lu

Shan Lu

Auto-generated profile, based on publicly available information

Shan Lu

Nanjing Medical University, School of Pharmacy, Nanjing, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
PDF file
YCYuying Cheng
Yuying Cheng
JLJian Liu
Jian Liu
YSYu Su
Yu Su
HZHuiru Zhao
Huiru Zhao
YZYujing Zhao
Yujing Zhao
JWJun Wu
Jun Wu
One common complication after joint arthroplasty is venous thromboembolism (VTE). Therefore, it is essential to measure the changes in coagulation and fibrinolysis in order to predict VTE among patients who underwent joint arthroplasty. This study aimed to identify potential useful biomarkers for prognosing to VTE. This was a prospective cohort study enrolling 83 patients who underwent joint arthroplasty. The levels of d-dimer, thrombin–antithrombin complex (TAT), plasmin–α2-antiplasmin complex (PIC), soluble thrombomodulin, and tissue plasminogen activator inhibitor complex were measured on day 0 (before surgery) and days 1, 3, and 6 after surgery. Ultrasound examination was used to diagnose VTE on preoperative day 0 and postoperative day 6. A total of 35 patients developed VTE after surgery. Patients with VTE exhibited significantly higher levels of d-dimer and TAT on postoperative days 3 and 6 (all P < .05). The area under curves (AUC) of receiver operating characteristic (ROC) were 0.65 and 0.68 and 0.68 and 0.74 for d-dimer and TAT levels on postoperative days 3 and 6, respectively. The level of TAT/PIC ratio on postoperative day 6 was significantly increased among patients with VTE compared to non-VTE patients (P < .0001). In addition, the AUC of ROC, cutoff level, sensitivity, specificity, positive-predictive value, and negative-predictive value of TAT/PIC ratio were 0.78, 4.03 ng/TU, 97.14%, 33.33%, 51.52%, and 94.12%, respectively. The high sensitivity and negative predictive value of TAT/PIC ratio make it a potential prognostic index for diagnosing VTE during the early phase of postoperative joint arthroplasty.

1 January 2020 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
PDF file
WRWenhua Ren
Wenhua Ren
JZJing Zhang
Jing Zhang
YCYuying Chen
Yuying Chen
MWMeng Wen
Meng Wen
YSYu Su
Yu Su
JWJun Wu
Jun Wu
To evaluate variations in coagulation, fibrinolysis and endothelial marker expression in cirrhotic patients and to explore their clinical value and predictive performance in cirrhotic patients with or without portal vein thrombosis (PVT), we performed a case-control study with 175 cirrhotic patients and 50 healthy individuals. 99 patients had PVT and another 76 patients did not. All participants were evaluated for plasma levels of conventional hemostatic markers. Thrombin-antithrombin complex (TAT), plasmin-α2-plasmin inhibitor complex (PIC), thrombomodulin (TM), tissue plasminogen activator inhibitor complex (t-PAIC), von Willebrand factor antigen (vWF: Ag) and coagulation factor Ⅷ (FⅧ: c) were also assessed and the ratio of TAT/t-PAIC was calculated. We analyzed differences in these biomarkers among the three groups and constructed receiver operating characteristic (ROC) curves. Patients with PVT exhibited significantly higher TAT and TAT/t-PAIC than cirrhotic patients without PVT (both P < 0.001). Areas under the curve (AUC) of ROC analyses for TAT and TAT/t-PAIC were 0.68 and 0.66, the cut-off levels were 1.55 ng/ml and 0.46, with sensitivities and specificities of 78.79% and 51.32% regarding TAT, 39.8% and 90.79% regarding TAT/t-PAIC. Levels of FⅧ: c and vWF: Ag in patients with PVT were significantly lower than those without PVT (p = 0.026 and p = 0.027, respectively). The AUCROC, cut-off level, sensitivity and specificity of FⅧ: c were 0.64, 111.1%, 66.67% and 60%, respectively. For vWF: Ag they were 0.61, 429%, 89.66% and 38.71%, respectively. Cirrhotic patients have disorders of coagulation, fibrinolysis and the endothelial system. TAT, TAT/t-PAIC, FⅧ: c and vWF: Ag can be used as potential biomarkers for predicting PVT in cirrhotic patients.

11 May 2025 in The Journal of Physiology
Verified
Journal Article
Open access
SLShan Lu
Shan Lu
MBMaria Baier
Maria Baier
RPRisto‐Pekka Polonen
Risto‐Pekka Polonen
ZLZhandi Liao
Zhandi Liao
JMJody L. Martin
Jody L. Martin
DBDonald Bers
Donald Bers
Background: Diabetic cardiomyopathy (DbCM) preclinical studies have used animal models from different species and implicated altered redox regulation and reactive oxygen species (ROS) in this disease. However hyperglycaemia‐induced ROS signalling may differ in ventricular myocytes from different species, and here we compare mice, rats, rabbits and humans with respect to hyperglycaemia‐induced ROS production. Methods: Using the chemical sensor H2DCFDA and genetically encoded redox sensors, we measured time‐dependent ROS signals in response to high glucose (HiGlu). Live cell confocal imaging was used to determine redox and glucose levels, contractility and Ca2+ transients in isolated cardiomyocytes. Western blotting and activity assays were used to evaluate superoxide dismutase (SOD) expression and activity. Results: Consistent with our prior mouse studies, HiGlu exposure in rat and human ventricular myocytes increased cytosolic (not mitochondrial) ROS production via a mechanism involving Ca‐calmodulin‐dependent protein kinase (CaMKII) O‐GlcNAcylation (at Ser280) and NADPH oxidase 2 (NOX2) activation. However in rabbit ventricular myocytes HiGlu alone did not induce significant ROS production, unless complemented by low levels of angiotensin II and inhibition of the enzyme that reverses O‐GlcNAcylation using 100 nM Thiamet G, where both cytosolic and mitochondrial ROS accumulation were involved by more complex signalling networks. Conclusion: Acute hyperglycaemia readily induces robust ROS production in mouse, rat and human ventricular myocytes, but rabbit myocytes are intrinsically better protected from this HiGlu‐induced ROS responses. In most regards rabbit are much more human‐like than rodents for many aspects of myocyte function, but this surprisingly is not the case for HiGlu‐induced ROS production. image Key points: In mouse ventricular myocytes we previously showed that acute hyperglycaemia (HiGlu) induced increase in reactive oxygen species (ROS) mediated by O‐GlcNAcylation of Ca‐calmodulin‐dependent protein kinase at Ser280 and consequent NADPH oxidase 2 (NOX2) activation. Here we demonstrate that this same pathway is functional in human and rat ventricular myocytes but not in rabbit ventricular myocytes. In rat and human myocytes HiGlu induced an increase in cytosolic, but not mitochondrial, ROS production. In rabbit myocytes HiGlu only produced increased ROS (cytosolic and mitochondrial) only when it was accompanied by both low concentration angiotensin II and an O‐GlcNAcylase inhibitor (that individually did not promote ROS production). This direct HiGlu‐induced ROS production in cardiac myocytes may contribute to pathological signalling in diabetes.

29 August 2025 in Circulation Research
Verified
Journal Article
Closed access
ZGZhiye Guo
Zhiye Guo
XDXiaolong Du
Xiaolong Du
CXChunlei Xing
Chunlei Xing
ZSZhiguang Shi
Zhiguang Shi
DXDandan Xu
Dandan Xu
SLShan Lu
Shan Lu
BACKGROUND: Deep vein thrombosis (DVT), the third most common cause of cardiovascular deaths, is characterized by intravascular clot formation, often accompanied by inflammation. Although the STING (stimulator of interferon genes) signaling pathway is well recognized for its role in mediating inflammation in the context of infection, cellular stress, and tissue, its intricate involvement in DVT remains enigmatic. METHODS: In this study, we investigated the role of myeloid cell–intrinsic STING signaling in DVT progression using murine models. Both STING inhibitors and genetic depletion of myeloid-specific STING were used to assess their effects on thrombus formation. In addition, we explored the interaction between STING and YBX1 (Y-box-binding protein 1) through biochemical analyses. A synthetic peptide, C-ST16 (cell penetrating peptide [CPP]-segment), designed to mimic STING inhibitors, was tested for its therapeutic potential in reducing thrombus formation and inflammatory responses. RESULTS: Our results demonstrate that myeloid cell–intrinsic STING signaling is a key driver in DVT progression. STING inhibition, either through specific inhibitors or genetic depletion of myeloid-specific STING, significantly ameliorated thrombus formation in murine DVT models. Furthermore, we identified a direct interaction between STING and YBX1, resulting in nuclear translocation and heightened thrombotic inflammation. The synthetic peptide, C-ST16, effectively reduced thrombus formation and inflammatory factor expression, without causing hepatorenal toxicity. CONCLUSIONS: These findings highlight the critical role of myeloid-specific STING-YBX1 signaling in driving inflammation during DVT progression. The potential therapeutic use of STING inhibitors, particularly the synthetic peptide C-ST16, presents a promising approach for DVT management, offering novel insights into targeted anti-inflammatory therapies for thrombotic disorders.

14 June 2026 in BMEMat
Verified
Journal Article
Open access
WTWei Tang
Wei Tang
HSHao Sun
Hao Sun
CDChenqi Duan
Chenqi Duan
JCJiajia Chang
Jiajia Chang
YWYuxing Wang
Yuxing Wang
DHDa Huo
Da Huo
In vitro‐differentiated cardiomyocytes hold considerable promise for cardiac repair; however, their clinical translation has been critically hindered by persistent immaturity. Our study introduces an innovative strategy utilizing inducible inter‐organelle proximity to promote accelerated maturation. This is achieved through a synthetic “organelle glue” (OG) that physically links mitochondria and the endoplasmic reticulum, thereby stabilizing mitochondria–ER contact sites (MERCS). The OG structure was systematically refined to ensure optimal stabilization of MERCS. Detailed transcriptomic and metabolomic analyses were conducted to unravel the molecular and metabolic mechanisms underlying cardiomyocyte maturation driven by inducible MERCS. Electrophysiological and fluorescence‐based evaluations further validated the robust capacity of OG to advance maturation across various cellular models, including primary neonatal cardiomyocytes, induced pluripotent stem cell‐derived cardiomyocytes, and 3D cardiac organoids. Crucially, our findings demonstrate the ability to induce rapid, extensive, and functionally stable maturation in differentiated cardiomyocytes, offering compelling evidence for the therapeutic potential of manipulating organelle connectivity in cardiac tissue engineering.

17 June 2026 in Nature Communications
Verified
Journal Article
Open access
NGNa Geng
Na Geng
TCTaiwei Chen
Taiwei Chen
HLHao Li
Hao Li
SLShan Lu
Shan Lu
YWYuehong Wang
Yuehong Wang
XLXiyuan Lu
Xiyuan Lu
Heart failure (HF) is a growing global health burden characterized by impaired cardiac contractility and progressive remodeling, driven in part by disrupted Ca 2+ handling and mitochondrial dysfunction. However, the molecular mechanisms coordinating these processes remain incompletely understood. Here we showed that OPA3 was decreased in both human and murine HF. Cardiomyocyte-specific deletion of Opa3 in male mice led to the progressive dilated cardiomyopathy (DCM), accompanied by impaired myocardial function, calcium cycling and mitochondria function. Mechanistically, OPA3 forms multimers that are required for its interaction with phospholamban (PLN), thereby maintaining sarcoplasmic reticulum (SR) Ca 2+ -ATPase (SERCA2a) activity and Ca 2+ handling. OPA3 is localized to the mitochondrial outer membrane, and its absence impaired mitochondrial function. Cardiomyocyte-specific overexpression of Opa3 improved cardiac dysfunction in both pressure overload- and doxorubicin-induced HF models. Our data define a critical role of OPA3-PLN-SERCA2a axis that regulates both mitochondria and SR function, representing a potential therapeutic target for HF.